Explore private companies that have undergone mergers or acquisitions.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids | $ Total Asks | # Bids | # Asks | Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Vividion Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $267.82MM | Series C | 2/24/2021 | $135MM | $600.09MM | $2.10 | Logos Capital, Boxer Capital, SoftBank, Avoro Capital Advisors, BlackRock, RA Capital Management, T. Rowe Price Associates, Surveyor Capital, Woodline Partners, Acuta Capital, Driehaus Capital Management, ARCH Venture Partners, BVF Partners, Casdin Capital, Mubadala Capital, Nextech Invest, Versant Ventures | |||||
| RayzeBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $795.51MM | Series D | 9/13/2022 | $159.75MM | $599.64MM | $2.50 | Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital | |||||
| Aetion | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $411.43MM | Series C | 5/11/2021 | $110MM | $585.67MM | $13.13 | Warburg Pincus, B Capital, Foresite Capital, New Enterprise Associates, Flare Capital Partners | |||||
| Truepill | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $929.28MM | Series E-1 | 8/16/2023 | $7.49MM | $541.17MM | $22.68 | Undisclosed Investors | |||||
| Shoreline Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $186MM | Series B | 11/2/2021 | $140MM | $527.99MM | $10.07 | Ally Bridge Group, Eventide Asset Management, BeiGene, Irving Investors, Kingdon, NS Investment, Piper Heartland Healthcare Capital, Superstring, BVF Partners, Commodore Capital, Cormorant Asset Management, Janus Henderson Investors, Kite, Stork Capital, Wedbush Healthcare Partners | |||||
| Capstan Therapeutics | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $845MM | Series B | 3/20/2024 | $175MM | $525.33MM | $3.37 | RA Capital Management, Forbion, Johnson & Johnson, Mubadala Capital, Perceptive Advisors, Sofinnova Investments, Alexandria Venture Investments, Bristol Myers Squibb, Eli Lilly, Bayer, Novartis Venture Fund, OrbiMed, Pfizer Ventures, Polaris Partners, Vida Ventures | |||||
| Omniome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $153.29MM | Series C | 1/9/2020 | $60MM | $511MM | $4.17 | Madrone Capital Partners, ARCH Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Science Ventures, Nan Fung Life Sciences | |||||
| Akili | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $275.08MM | Series D | 5/26/2021 | $151.68MM | $452.34MM | $8.43 | Neuberger Berman Funds, Polaris Partners, Mirae Assets, Shionogi & Co LTD, New Leaf Venture Partners, Dave Baszucki, QUAD Investment Management, Ladera Venture Partners, Temasek, Baillie Gifford, JAZZ Venture Partners, Evidity Health Capital, Omidyar Technology Ventures, Fearless Ventures, Amgen Ventures, M Ventures | |||||
| Chroma Medicine | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $262MM | Series B | 3/1/2023 | $135MM | $450.56MM | $2.60 | ARCH Venture Partners, DCVC Bio, Mubadala Capital, Sixth Street, Alexandria Venture Investments, Atlas Venture, Casdin Vapital, Cormorant Asset Management, Janus Henderson Investors, Newpath Partners, Omega Funds, Osage University Partners, Sofinnova Partners, T Rowe Price, Wellington Management | |||||
| Aiolos Bio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $247.55MM | Series A | 10/24/2023 | $180MM | $436.12MM | $1.19 | Atlas Venture, Bain Capital Life Sciences, Forbion, Sofinnova Investments, RA Capital Management | |||||
| PatientPop | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $125.82MM | Series C | 8/25/2020 | $42.65MM | $425.93MM | $9.93 | HLM Venture Partners, Commonfund, Vivo Capital, Toba Capital, Transformation Capital, Silicon Valley Bank | |||||
| Memora Health | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $90.4MM | Series A-1 | 4/18/2023 | $30MM | $420MM | $3.22 | General Catalyst, Northwell Holdings, NorthShore, Edward Elmhurst Health, PagsGroup, Andreessen Horowitz, Transformation Capital, Frist Cressey Ventures | |||||
| Kareo | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $136.5MM | Series H | 10/9/2018 | $10MM | $414.8MM | $6.86 | Undisclosed Investors | |||||
| IDRx | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $242.24MM | Series B | 8/7/2024 | $120.24MM | $414.65MM | $6.44 | RA Capital Management, Commodore Capital, Blackstone, Rock Springs Capital, Andreessen Horowitz, Forge Life Science Partners, Nick Lydon, Merck, Nextech Invest | |||||
| Twill | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $90.83MM | Series D | 3/17/2021 | $31MM | $409.29MM | $8.14 | Deerfield Management Company, Omega Capital Partners, ION Crossover Partners | |||||
| Elektrofi | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $284.44MM | Series C | 8/8/2024 | $96.45MM | $402.83MM | $14.04 | Undisclosed Investors | |||||
| Medly Pharmacy | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $297.45MM | Series C-1 | 7/29/2022 | $51.86MM | $389.1MM | $0.20 | Undisclosed Investors | |||||
| Arthrosi Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $294.54MM | Series E | 10/8/2025 | $148.1MM | $385.03MM | $6.54 | Prime Eight Capital, CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech | |||||
| Nalu | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $331.77MM | Series E | 10/9/2024 | $115.06MM | $382.56MM | $4.85 | Novo Holdings, Gilde Healthcare, MVM Partners, Endeavour Vision, Decheng Capital, Longitude Capital, Advent Life Sciences, Pura Vida, Aperture Venture Partners, B Capital | |||||
| Eden Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $98.78MM | Series C | 2/18/2021 | $60MM | $382.34MM | $4.67 | Insight Partners, Amigos Health, Aspect Ventures, Company Ventures, Flare Capital, Flexcap Ventures, Max Ventures, PJC | |||||
| Bluejay Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $242.24MM | Series C-1 | 5/9/2024 | $1.14MM | $371.77MM | $6.53 | Frazier Life Sciences, RA Capital Management, T. Rowe Price, Wellington Management, Novo Holdings, RiverVest Venture Partners, Octagon Capital, Arkin Bio Ventures, HBM Healthcare Investments, Unicorn Capital | |||||
| CinCor Pharma | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $192.86MM | Series B | 10/12/2021 | $142.86MM | $370.57MM | $4.00 | General Atlantic, Perceptive Advisors, BVF Partners, venBio Partners, Adage Capital Management, Omega Funds, Rock Springs Capital, RTW Investments, Lilly Asia Ventures, Sixty Degree Capital, Sofinnova Investments, Sofinnova Partners, 5AM Ventures, CinRx | |||||
| Kyruus | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $192.53MM | Series E | 9/15/2022 | $35.1MM | $359.84MM | $23.40 | Undisclosed Investors | |||||
| Apexigen | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $xx.xx | $xx.xx | xx | xx | Not available | -- | -- | $165.38MM | Series C | 3/24/2020 | $127.86MM | $343.82MM | $1.55 | Decheng Capital, Oceanpine Capital, 3E Bioventures Capital, VI Ventures, SV Tech Ventures, H&Q Asia Pacific, LDV Ventures, ShangBay Capital, Delian Capital, Hua Nan Venture Capital, Efung Capital | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.